Evidence map›Paper›PMID 36181265›Full record

ArticleNeuropathology and applied neurobiology2023

Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis.

Simon Licht-Mayer, Graham R Campbell, Arpan R Mehta, Katie McGill, Alex Symonds, Sarah Al-Azki, Gareth Pryce, Stephanie Zandee, Chao Zhao, Markus Kipp and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Neuropathology and applied neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Hypoxia in multiple sclerosis.Redox biology · 2025
    Review
  7. Article
  8. How to Use the Cuprizone Model to Study De- and Remyelination.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Multiple Sclerosis: Inflammatory and Neuroglial Aspects.Current issues in molecular biology · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 5 countries.

Simon Licht-MayerCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Graham R CampbellCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Arpan R MehtaCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Katie McGillCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Alex SymondsCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Sarah Al-AzkiBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Gareth PryceBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Stephanie ZandeeCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.ORCID https://orcid.org/0000-0003-0812-676X
Chao ZhaoWellcome Trust-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Markus KippInstitute of Anatomy, Rostock University Medical Center, Rostock, Germany.
Kenneth J SmithDepartment of Neuroinflammation, The UCL Queen Square Institute of Neurology, University College London, London, UK.
David BakerBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Daniel AltmannFaculty of Medicine, Department of Medicine, Hammersmith Campus, London, UK.
Stephen M AndertonCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
Yolanda S KapDepartment of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
Jon D LamanDepartment of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
Bert A 't HartDepartment of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
Moses RodriguezDepartment of Neurology and Immunology, Mayo College of Medicine and Science, Rochester, Minnesota, USA.
Robin J M FranklinWellcome Trust-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Siddharthan ChandranCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Hans LassmannDepartment of Neuroimmunology, Center for Brain Research, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-8617-5052
Bruce D TrappDepartment of Neuroscience, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Don J MahadCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
University of Edinburgh · GBQueen Mary University of London · GBCentre for Inflammation Research · GBUK Dementia Research Institute · GBUniversity Medical Center Groningen · NLWellcome/MRC Cambridge Stem Cell Institute · GBBiomedical Primate Research Centre · NLCleveland Clinic Lerner College of Medicine · USHammersmith Hospital · GBMayo Clinic · USMedical University of Vienna · ATUniversity of Rostock · DE

Funding

Pathogenesis of Neurological Disability in Primary Diseases of MyelinR35NS097303 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI TRAPP, BRUCE D · 2017 to 2024
$6.9M
Medical Research Council MC_EX_MR/N50192X/1Medical Research Council MR/R001162/1Motor Neurone Disease Association MEHTA/JUL17/948-795Multiple Sclerosis SocietyNINDS NIH HHS R35 NS097303
6 · The paper itself

Abstract

aimsAxonal injury in multiple sclerosis (MS) and experimental models is most frequently detected in acutely demyelinating lesions. We recently reported a compensatory neuronal response, where mitochondria move to the acutely demyelinated axon and increase the mitochondrial content following lysolecithin-induced demyelination. We termed this homeostatic phenomenon, which is also evident in MS, the axonal response of mitochondria to demyelination (ARMD). The aim of this study is to determine whether ARMD is consistently evident in experimental demyelination and how its perturbation relates to axonal injury.

methodsIn the present study, we assessed axonal mitochondrial content as well as axonal mitochondrial respiratory chain complex IV activity (cytochrome c oxidase or COX) of axons and related these to axonal injury in nine different experimental disease models. We used immunofluorescent histochemistry as well as sequential COX histochemistry followed by immunofluorescent labelling of mitochondria and axons.

resultsWe found ARMD a consistent and robust phenomenon in all experimental disease models. The increase in mitochondrial content within demyelinated axons, however, was not always accompanied by a proportionate increase in complex IV activity, particularly in highly inflammatory models such as experimental autoimmune encephalomyelitis (EAE). Axonal complex IV activity inversely correlated with the extent of axonal injury in experimental disease models.

conclusionsOur findings indicate that ARMD is a consistent and prominent feature and emphasise the importance of complex IV activity in the context of ARMD, especially in autoimmune inflammatory demyelination, paving the way for the development of novel neuroprotective therapies.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisAnimalsAxonsMitochondriaNeuronsaxon injurycomplex IVexperimental demyelinationmitochondriamultiple sclerosis and neuroprotection

Identifiers

PMID36181265
PMCPMC10092519
OpenAlexW4298326279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.